Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,148
datasets available to search
ShareScore release 0.9.0
Dataset results
2,148 results for “HER2”
Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
ClinicalTrials.gov study NCT06344780. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast
ClinicalTrials.gov study NCT03812393. IPD Sharing: NO. Countries: 1. Publications: 2.
Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
ClinicalTrials.gov study NCT04001621. IPD Sharing: Not stated. Countries: 1. Publications: 1.
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
ClinicalTrials.gov study NCT05870579. IPD Sharing: NO. Countries: 7. Publications: 1.
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
ClinicalTrials.gov study NCT06278870. IPD Sharing: NO. Countries: 1. Publications: 13.
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Ex
ClinicalTrials.gov study NCT05408845. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
ClinicalTrials.gov study NCT02732119. IPD Sharing: YES. Countries: 1. Publications: 0.
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
ClinicalTrials.gov study NCT05150652. IPD Sharing: NO. Countries: 1. Publications: 1.
Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer
ClinicalTrials.gov study NCT04899128. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer
ClinicalTrials.gov study NCT00140738. IPD Sharing: YES. Countries: 5. Publications: 1.
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
ClinicalTrials.gov study NCT05054751. IPD Sharing: NO. Countries: 1. Publications: 1.
EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan
ClinicalTrials.gov study NCT05458401. IPD Sharing: NO. Countries: 3. Publications: 1.
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
ClinicalTrials.gov study NCT00005970. IPD Sharing: Not stated. Countries: 4. Publications: 13.
A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.
ClinicalTrials.gov study NCT02576548. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preopera
ClinicalTrials.gov study NCT04873362. IPD Sharing: YES. Countries: 32. Publications: 1.
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
ClinicalTrials.gov study NCT05660083. IPD Sharing: NO. Countries: 1. Publications: 30.
Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors
ClinicalTrials.gov study NCT04146610. IPD Sharing: NO. Countries: 1. Publications: 1.
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
ClinicalTrials.gov study NCT04053322. IPD Sharing: Not stated. Countries: 1. Publications: 1.
BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer
ClinicalTrials.gov study NCT01320280. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma
ClinicalTrials.gov study NCT05504720. IPD Sharing: NO. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.